Skip to main content
SpringerLink
Log in

Radioguided Surgery of Occult Lesions in Patients with Thyroid Cancer

  • Chapter
Radioguided Surgery

  • 742 Accesses

Abstract

In patients with well-differentiated thyroid carcinoma, poorly differentiated thyroid carcinoma, and medullary thyroid carcinoma, surgery is the first and most important modality of treatment (1). The extent of the surgery is debatable, although most clinicians currently recommend total or near-total thyroidectomy for all clinically obvious thyroid tumors (2), to reduce local recurrence rates. This is supported by follow-up studies demonstrating that the completeness of surgical excision is an independent prognostic indicator for survival (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Shaha AP. Management of the neck in thyroid cancer. Otorhinolaryngol Clin North Am. 1998;31:823–831.

    Article  CAS  Google Scholar 

  2. Schlumberger M, Pacini F. Thyroid Tumors. Paris: Editions Nucleon; 2003.

    Google Scholar 

  3. Hay ID, Bergstrahl EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1058.

    CAS  PubMed  Google Scholar 

  4. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463.

    Article  CAS  PubMed  Google Scholar 

  5. American Joint Committee of Cancer. Thyroid. In: AJCC Cancer Staging Handbook. 6th edition. New York: Springer; 2002:89–98.

    Google Scholar 

  6. Kebebew E, Ituarte PHG, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and comparison of staging systems. Cancer. 2000;88:1139–1148.

    Article  CAS  PubMed  Google Scholar 

  7. Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;99:60–66.

    CAS  PubMed  Google Scholar 

  8. Travagli JP, Cailleux AF, Ricard M, et al. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:2675–2860.

    Article  CAS  PubMed  Google Scholar 

  9. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluoro-deoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107–1113.

    Article  CAS  PubMed  Google Scholar 

  10. Lippi F, Capezzone M, Miccoli P, et al. Use of surgical gamma probe for the detection of lymph node metastases in differentiated thyroid cancer. Tumori. 2000;86:367–369.

    CAS  PubMed  Google Scholar 

  11. Salvatori M, Rufini V, Reale F, et al. Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer. World J Surg. 2003;27:770–775.

    Article  PubMed  Google Scholar 

  12. Boz A, Arici C, Güngör F, et al. Gamma probe-guided resection and scanning with Tc-99m MIBI of a local recurrence of follicular thyroid carcinoma. Clin Nucl Med. 2001;26:820–822.

    Article  CAS  PubMed  Google Scholar 

  13. Rubello D, Piotto A, Pagetta C, Pelizzo MR, Casara D. 99mTc-MIBI radio-guided surgery for recurrent thyroid carcinoma: technical feasibility and procedure, and preliminary clinical results. Eur J Nucl Med. 2002;29:1201–1205.

    Article  CAS  Google Scholar 

  14. Peltier P, Curtet C, Chatal JF, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-Indium-DTPA antibody and a Indium-111-labeled DTPA dimer. J Nucl Med. 1993;34:1267–1273.

    CAS  PubMed  Google Scholar 

  15. Adams S, Baum RP, Hertel A, et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med. 1998;39:1155–1160.

    CAS  PubMed  Google Scholar 

  16. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using Indium-111 bivalent hapten and anti-CEA anti-DTPA-Indium bispecific antibody. J Nucl Med. 1998;39:1172–1178.

    CAS  PubMed  Google Scholar 

  17. Adams S, Baum RP. Intraoperative use of gammadetecting probes to localize neuroendocrine tumors. Q J Nucl Med. 2000;44:59–67.

    CAS  PubMed  Google Scholar 

  18. de Labriolet-Vaylet C, Cattan P, Sarfati E, et al. Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery. Clin Cancer Res. 2000;6:363–371.

    Google Scholar 

  19. Adams S, Acker P, Lorenz M, Staib-Sebler E, Hor G. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma. Cancer. 2001;92:263–270.

    Article  CAS  PubMed  Google Scholar 

  20. Voutilainen PE, Multanen MM, Leppaniemi AK, et al. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid. 2001;11:953–957.

    Article  CAS  PubMed  Google Scholar 

  21. Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46:28S–37S.

    CAS  PubMed  Google Scholar 

  22. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodione-131 therapy for well differentiated thyroid cancer. A quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33:1132–1136.

    PubMed  Google Scholar 

  23. Gallowitsh HJ, Fellinger J, Mikosch P, et al. Gamma probe-guided resection of a lymph node metastasis with I-123 in papillary thyroid carcinoma. Clin Nucl Med. 1997;22:591–592.

    Article  Google Scholar 

  24. Gulec SA, Eckert M, Woltering EA. Gamma probe-guided node dissection (“gamma picking”) in differentiated thyroid carcinoma. Clin Nucl Med. 2002;12:859–861

    Article  Google Scholar 

  25. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med. 1992;92:631–642.

    Article  CAS  PubMed  Google Scholar 

  26. Wartofsky L, Sherman SI, Gopal J, et al. Therapeutic controversy. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 1998;83:4195–4203.

    Article  CAS  PubMed  Google Scholar 

  27. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–76.

    CAS  PubMed  Google Scholar 

  28. Elser H, Henze M, Hermann C, Eckert W, Mende U. 99mTc-MIBI for recurrent and metastatic differentiated thyroid carcinoma. Nucklearmedizin. 1997;37:7–12.

    Google Scholar 

  29. Rubello D, Mazzarotto R, Casara D. The role of technetium-99m methoxy-isobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med. 1999;27:431–440.

    Article  Google Scholar 

  30. Yen TC, Lin HD, Lee CH, Chang SL, Yeh SH. The role of technetium-99m sestamibi whole-body scans in diagnosis of metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201. Eur J Nucl Med. 1994;21:980–983.

    Article  CAS  PubMed  Google Scholar 

  31. Franceschi M, Kusic Z, Franceschi D, Luiniac L, Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole body scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 1996;37:446–451.

    CAS  PubMed  Google Scholar 

  32. Rubello D, Salvatori M, Pelizzo MR, et al. Radio-guided surgery of differentiated thyroid cancer using 131I or 99mTc-Sestamibi. Nucl Med Commun. 2006;27:1–4.

    Article  PubMed  Google Scholar 

  33. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-Fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole-body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–2302.

    Article  CAS  PubMed  Google Scholar 

  34. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–76.

    CAS  PubMed  Google Scholar 

  35. Al-Nahhas A. Dedifferentiated thyroid carcinoma: the imaging role of 18F-FDG PET and non-iodine radiopharmaceuticals. Nucl Med Commun. 2004;25:891–895.

    Article  PubMed  Google Scholar 

  36. Desai DC, Arnold M, Saha S, et al. Correlative wholebody FDG-PET and intraoperative gamma detection of FDG distribution in colorectal cancer. Clin Positron Imaging. 2000;3:189–196.

    Article  PubMed  Google Scholar 

  37. Essner R, Hsueh E-C, Haigh P-I, et al. Application of an 18F-fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. J Surg Res. 2001;96:120–126.

    Article  CAS  PubMed  Google Scholar 

  38. Zervos EE, Desai DC, De Palatis LR, et al. 18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer. J Surg Res. 2001;97:9–13.

    Article  CAS  PubMed  Google Scholar 

  39. Essner R, Daghighian F, Giuliano AE. Advances in FDG PET probes in surgical oncology. Cancer J. 2002;8:100–108.

    Article  PubMed  Google Scholar 

  40. Barranger E, Kerrou K, Petegnief Y, David-Montefiore E, Cortez A, Darai E. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer. Gynecol Oncol. 2005;96:241–244.

    Article  PubMed  Google Scholar 

  41. Carrera D, Fernandez A, Estrada J, Martin-Comin J, Gamez C. Detection of occult malignant melanoma by 18F-FDG PET-CT and gamma probe. Rev Esp Med Nucl. 2005;24:410–413.

    Article  CAS  PubMed  Google Scholar 

  42. Franc BL, Mari C, Johnson D, Leong SP. The role of a positron-and high-energy gamma photon probe in intraoperative localization of recurrent melanoma. Clin Nucl Med. 2005;30:787–791.

    Article  PubMed  Google Scholar 

  43. Meller B, Sahlmann C, Horstmann O, Gerl J, Bahere M, Meller J. Conventional gamma and high-energy probe for radioguided dissection of metastases in a patient with recurrent thyroid carcinoma with 99mTc-MIBI and 18F-FDG. Nuklearmedizin. 2005;44:N23–N25.

    CAS  PubMed  Google Scholar 

  44. Kraeber-Bodéré F, Cariou B, Curtet C, et al. Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. Surgery. 2005;138:1176–1182 (discussion 1182)

    Article  PubMed  Google Scholar 

  45. Robbins KT, Atkinson JLD, Byers RM, Cohen JI, Lavertu P, Pellitteri P. The use and misuse of neck dissection for head and neck cancer. J Am Coll Surg. 2001;193:91–102.

    Article  CAS  PubMed  Google Scholar 

  46. Gordon PR, Huvos AG, Strong EW. Medullary carcinoma of the thyroid gland. A clinicopathology study of 40 cases. Cancer. 1973;31:915–924.

    Article  CAS  PubMed  Google Scholar 

  47. Wilson PC, Millar BM, Brierley JD. The management of advanced thyroid cancer. Clin Oncol. 2004;16:561–568.

    Article  CAS  Google Scholar 

  48. Tisell LE, Ahlman H, Wangberg B, et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg. 1997;84:543–547.

    Article  CAS  PubMed  Google Scholar 

  49. Waddington WA, Kettle AG, Heddle RM, Coakley AJ. Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med. 1994;21:363–364.

    Article  CAS  PubMed  Google Scholar 

  50. Ahlman H. Radioisotope-guided surgery in patients with neuroendocrine tumors. Digestion. 1996;57(suppl 1):88–89.

    Article  PubMed  Google Scholar 

  51. Wangberg B, Forssel-Aronsson E, Tisell LE, Nilsson O, Fjalling M, Ahlman H. Intraoperative detection of somatostatin-receptor positive neuroendocrine tumors using indium-111 labelled DTPA-D-Phe1-octreotide. Br J Cancer. 1996;73:770–775.

    CAS  PubMed  Google Scholar 

  52. Benjegard SA, Forssell-Aronsson E, Wangberg B, Skanberg J, Nilsson O, Ahlman H. Intraoperative tumor detection using 111In-DTPA-d-Phe1-octreotide and a scintillation detector. Eur J Nucl Med. 2001;28:1456–1462.

    Article  CAS  PubMed  Google Scholar 

  53. Busnardo B, Girelli ME, Simonini N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53:278–285.

    Article  CAS  PubMed  Google Scholar 

  54. O’Byrne KJ, Hamilton D, Robinson I, Sweeney E, Freyne PJ, Cullen MJ. Imaging of medullary carcinoma of the thyroid using 111In-labelled anti-CEA monoclonal antibody fragments. Nucl Med Commun. 1992;13:142–148.

    Article  PubMed  Google Scholar 

  55. Juweid M, Sharkey R, Behr RM, et al. Radioimmunotherapy of medullary thyroid carcinoma with iodine-131-labeled anti-CEA antibodies. J Nucl Med. 1996;37:905–911.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Service, PET Center, S. Maria della Misericordia Hospital, Istituto Oncologico Veneto (IOV), Rovigo, Italy

    Domenico Rubello MD

  2. Nuclear Medicine Service, Policlinico Gemelli, Catholic University of the Sacred Heart, Rome, Italy

    Massimo Salvatori MD

  3. Department of Surgery, University of Padua, Padua, Italy

    Maria Rosa Pelizzo MD

  4. Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa, Italy

    Giuseppe Boni MD & Giuliano Mariani MD

Authors
  1. Domenico Rubello MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Salvatori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Rosa Pelizzo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Boni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuliano Mariani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa, Italy

    Giuliano Mariani MD

  2. John Wayne Cancer Institute, Saint John’s Health Center, Santa Monica, California, USA

    Armando E. Giuliano MD (Chief of Science and Medicine) (Chief of Science and Medicine)

  3. Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    H. William Strauss MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rubello, D., Salvatori, M., Pelizzo, M.R., Boni, G., Mariani, G. (2008). Radioguided Surgery of Occult Lesions in Patients with Thyroid Cancer. In: Mariani, G., Giuliano, A.E., Strauss, H.W. (eds) Radioguided Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-38327-9_26

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-38327-9_26

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-33684-8

  • Online ISBN: 978-0-387-38327-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation